Program
HEC53856
A development code. Also written as “HEC53856 tablet”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by Sunshine Lake Pharma.
Furthest: phase 2, since Oct 14, 20264 company-led studies, 1 open or runningNext primary completion: Feb 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sunshine Lake Pharma | 41 open or running | phase 2since Oct 14, 2026 | Mar 19, 2019 | Feb 2028phase 2 · NCT07891377 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 19, 2019First study: phase 1 study in HealthyFirst studyNCT03886688 · 116 enrolled · China
- May 30, 20212 phase 1 studiesNCT04925674, NCT04925661
- Oct 14, 2026Phase 2 study in Chemotherapy-induced AnemiaPhase 2 reachedNCT07891377 · 160 planned · China
Ahead
- Feb 2028Primary completion: phase 2 study in Chemotherapy-induced AnemiaNCT07891377
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07891377Chemotherapy-induced Anemia · China | 2 | Not yet recruiting | Feb 2028 | 160 |
| NCT04925674Hemodialysis · China | 1 | Completed | Oct 19, 2022 | 60 |
| NCT04925661Renal Insufficiency, Chronic · China | 1 | Completed | Aug 29, 2023 | 40 |
| NCT03886688Healthy · China | 1 | Completed | Jan 1, 2020 | 116 |
How it is read
Names in the registry
- “HEC53856”, 3 entries
- “HEC53856 tablet”, 1 entry
Codes read as this program: HEC53856.
Conditions, from the studies’ own filings
- Anemia, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.